Skip to main content

Recent updates on Sintilimab in solid tumor immunotherapy


In recent years, there have been advancements in traditional patterns of tumor therapy with the adoption of immunotherapy. Its application with or without other combined regimens has attracted attention from clinicians. Sintilimab (Tyvyt®), a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. Sintilimab has been proven to be clinically beneficial in multiple solid tumor therapies. Combination therapy and monotherapy have shown potential and encouraging anti-tumor efficacy with controllable and acceptable toxicities. The combination therapy is more likely to be a novel and promising therapeutic option. This study provides an overview of the status of sintilimab-based clinical trials in various solid tumors.


Immune checkpoint proteins, including PD-1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), initiate signaling pathways that suppress T-cell anti-tumor effect [1].

Following the binding of immune checkpoint inhibitors (ICIs) to immune checkpoint proteins on the surface of T cells, tumor-mediated immune suppression is reversed [2]. Currently, clinical application of ICIs are mainly focused on anti-CTLA4 antibodies (ipilimumab, tremelimumab), anti-PD-1 antibodies (pembrolizumab, nivolumab, cemiplimab) and anit-PD-L1 antibodies (atezolizumab, avelumab and durvalumab). Hence, ICIs have immensely revolutionized and transformed cancer therapeutic modes [1, 3].

Sintilimab (Innovent Biologics, Suzhou, China), a type of PD-1 antibodies originally co-developed by Innovent Biologics, Eli Lilly and Company, has been approved for clinical management of either relapsed or refractory classical Hodgkin’s lymphoma (RR-c-HL)after more than second-line systematic chemotherapy [4]. Notably, Sintilimab was included in the 2019 edition of The Lymphoma Diagnosis and Treatment Guide of The Chinese Society of Clinical Oncology [4].

Preclinical efficacy of Sintilimab

Immune activation effects are maximized when immune checkpoint receptors are blocked and reach their saturation. This is mediated by both the concentration and the affinity of the antibody to the receptor. Despite anti-PD-1 antibodies (pembrolizumab (Keytruda, MK-3475) and nivolumab (Opdivo, MDX-1106)) exhibiting the highest affinity for human PD-1 and a lower off-rate, the PD-1 receptor occupancy of sintilimab on circulating T cells is superior, thus indicating a possibility of a continuous blockade of the PD-1-PD-L1/2 pathway [5] (Table 1). The drug occupies the binding site for a long time even after plasma concentrations have decreased, which may lengthen its effect [5].

Table 1 Affinity of Three Types of anti-PD-1 Antibodies [5]

Previous studies established that the sustained average PD-1 receptor occupancy rates on circulating T cells in patients administered with MDX1106 (dose-independent) and sintilimab were > 70 and > 95%, respectively [6, 7]. Besides, the immunogenicity of the drug affects its clinical efficacy. Protein drugs induce humoral immune responses, leading to the production of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) upon repeated injections [8]. This phenomenon has been closely associated with the reduction in efficacy and resistance to the antibody. In humanized mouse models, sintilimab was found to exhibit better anti-tumor effects than MDX-1106 and MK-3475 [5]. These findings demonstrate the potential of sintilimab as a novel, safe, effective anti-PD-1 antibody in the cancer immunotherapy regimens.

Clinical Progress of Sintilimab in application


A clinical trial (NCT03114683, ORIENT-1) by Shi et al, aimed at determining the efficiency and safety of sintilimab among the Chinese population, involved intravenous administration of sintilimab (200 mg, Q3W) to RR-cHL patients. There were no fatal cases associated with the clinical trial [6]. Among patients with RR-cHL, the objective response rate (ORR) with sintilimab was 80.4%, whereas nivolumab and pembrolizumab each had 69% [5]. These outcomes positioned sintilimab as an original strategy for RR-cHL patients [6]. Regarding the results of Shi et al, Ansell SM reported identical findings.. He stated the similar durable 6-month progression-free survival rate of 77.6% for sintilimab was highlighted when compared with 77% for nivolumab and 69% for pembrolizumab [9]. Moreover, RR-cHL patients with HIV following the administration of sintilimab experienced no fatal irAEs [10].

Application of triplet therapy of sintilimab with decitabine and GDP (gemcitabine, DDP, and dexamethasone), enhanced clinical responses in a diffuse large B-cell lymphoma (DLBCL) patient with 17p deletion who was irresponsive to the 1st and the 2nd line treatments [11].

Lung Cancer

Clinical trials

A trial of phase Ib in non-small lung cancer (NSCLC) was performed to evaluate the safety and efficacy of sintilimab in neoadjuvant therapy (registration number: ChiCTR-OIC-17013726). Two cycles of sintilimab (200 mg, 1st day and 22nd day) were administered to patients with resectable NSCLC at clinical-stage IA-IIIB followed by pulmonary operations after immunotherapy on the 43rd day. The patients achieved disease control rates (DCR), major pathologic response (MPR) and pathologic complete responses (pCR) of 90%, 40.5% and 16.2%, respectively. Toxicities from the administration were usually grade 1/2, indicating that patients with early-stage NSCLC could benefit from neoadjuvant immunotherapy and be well-tolerated [12]. Furthermore, it was established that a decrease in the SUV value of Positron Emission Tomography-Computed Tomography (PET-CT) may be used as a predictor for the pathological responses of NSCLC after sintilimab treatment [12].

In addition to neoadjuvant therapy, a combination of sintilimab and anlotinib (12 mg/d, 2 weeks on/1 week off) was investigated as a first-line choice for patients with NSCLC, which was a single-arm of phase I clinical trial (NCT03628521). According to the interim analysis, the ORR and disease control rate (DCR) was 77.3% and 100%, respectively. As for safety, 31.8% of 22 patients exhibited grade 3–4 treatment related adverse events (TRAE). The most frequent was hematuria. AEs were tolerable from the outcome, indicating an eminent anti-tumor effect due to the combination of anti-PD-1 with multi-target anti-angiogenesis drugs [13].

A randomized, double-blind, multi-center, phase III study (NCT03607539, ORIENT-11) was performed to compare sintilimab or placebo plus chemotherapy (pemetrexed and cisplatin/carboplatin) in treatment-naïve patients with locally advanced or metastatic non-squamous NSCLC and without sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic aberration. After a median follow-up of 8.9 months, the median progression-free survival (mPFS) of the sintilimab group against the placebo group was 8.9 and 5.0 months (p < 0.00001), respectively. The PFS rates at 6 months was 68.3% for sintlimab-combination and 42.0% for placebo-combination. The PFS benefit in the sintilimab-combination group was observed in all PD-L1 subgroups. Although the median overall survival (mOS) data for the two groups were not met, it showed that the sintilimab group tended to precede the control at the 6th month. The ORR was 51.9% in the sintilimab-combination group and 29.8% in the placebo-combination group, respectively. The incidence of grade 3–4 AEs was 61.7% in the sintilimab-combination group and 58.8% in placebo-combination group while DCR was higher in the sintilimab-combination group (86.8%, 95% CI: 82.2–90.7) than in the placebo-combination group (75.6%, 95% CI, 67.3–82.7). With a manageable safety and tolerability profile in patients, a combination of sintilimab and chemotherapy exhibited a tremendous potential as a first-line regimen for non-squamous NSCLCs [14].

On the European Society for Medical Oncology (ESMO) congress 2020, ORIENT-12 (NCT03629925) was reported, a randomized, double-blind, phase III study to evaluate the safety and efficacy of sintilimab plus gemcitabine and platinum (GP) as a first-line option for patients with either locally advanced or metastatic squamous NSCLC. Regardless of PD-L1 expression (TPS ≥1% or < 1%), the combination was shown to benefit patients in mPFS (5.9 m vs 4.9 m, HR, 0.575; 95% CI 0.435–0.761; P = 0.00009), with an acceptable safety profile [15]. The OS data have not been reported yet.

A phase of Ib clinical trial (NCT02937116) was designed to assess the efficacy and safety of sintilimab-chemotherapy as a first-line therapeutic option  for both nsqNSCLC and sqNSCLC. In this study, 21 patients (pts) and 20 pts. were enrolled in nsqNSCLC group and sqNSCLC group, respectively. ORR was found to be 68.4% and 64.7%, respectively. mPFS was found to be 12.6 months and 6.5 months in the nsqNSCLC cohort and sqNSCLC cohort, respectively. Moreover, the mOS data were evaluated to be 18.9 months and 15.4 months in the nsqNSCLC group and sqNSCLC group, repectively.

It revealed that 90.5% of the participants suffered AEs in the nsqNSCLC cohort, with neutropenia being the most significant. The ratio of grade 3–4 AEs was 38.1% in the nsqNSCLC cohort, while in the sqNSCLC cohort, the AEs incidence was up to 100%, among which the most common was white blood cell (WBC) count decline. The proportion of grade 3–4 AEs was 85%. There were no fatal events associated with treatments in both two cohorts. The most frequent sintilimab-related AEs were ALT increase, most of which were grade 1–2. Comparatively, sintilimab-chemo therapy exhibited a higher incidence and severity of AEs in sqNSCLC than in nsqNSCLC.

Notably, the study revealed that PD-L1 expression, whether tumor proportion score (TPS) ≥ 1% or TPS < 1%, was not correlated with clinical response, and neither did the tumor mutation burden level (TMB). A high TCR Change (TCRC) clonality (> 1) was significantly associated with a better OS, while a low TCRC diversity (< 1) was closely related with a superior PFS [16].

Hitherto, a combination of sintilimab and chemotherapy has been used in advanced NSCLC. Unlike previous, studies that deemed PD-L1 expression to be a predictor for the evaluation of tumor efficacy post-immunotherapy [17], the predictive role of this parameter might be overturned upon sintilimab administration on patients with NSCLC. This outcome requires more large-scale clinical trials to be confirmed.

Case series

An elderly man diagnosed with stage IVb lung adenocarcinoma without the driver-gene mutation achieved a partial remission (PR) after being administered with a total of five cycles of sintilimab (Q3W, 200 mg) combined with pemetrexed plus carboplatin. The curative effect lasted for about 3 months after the discontinuation of sintilimab with chemotherapy due to cardiac and skin adverse events. However, the PFS was over 9 months [18], which coincided with the outcome of ORIENT-11 [14].

Not only the combination of sintilimab with GP but also the administration of sintilimab with nedaplatin plus paclitaxel on a stage IIIB squamous NSCLC(T3N2M0) patient showed an encouraging anti-tumor effect. After 3 cycles of treatments, the TPS of the patient dropped from 80% to 0% [19], demonstrating the potential therapeutic value of sintilimab in resectable NSCLC. In another study, a combination of sintilimab plus bevacizumab was administered on a stage IIIB lung adenocarcinoma patient with EGFR exon 19 del mutation to achieve a 6-month PFS, thus suggesting tolerance as well as safety [20].

Apart from NSCLC, sintilimab was used against small cell lung cancer (SCLC). The patient responded well because the sum of the diameter of the target lesions reduced by 12.23% following two cycles of sintilimab (3.5 mg/kg) along with docetaxel (1.5 mg/kg). However, due to paraneoplastic neurological syndromes (PNSs), sintilimab efficacies were terminated [21].

Hepatocellular carcinoma

The regimen of sintilimab (200 mg, Q3W) and IBI305 (a bevacizumab biosimilar, 15 mg/kg, Q3W) was once used to manage on a patient with HBV-associated HCC multiple pulmonary metastases, low microsatellite instability (MSI-L), high PD-L1 expression and TMB-L. In this patient, there was a complete remission (CR) after 2 cycles of administration and the level of alpha-fetoprotein (AFP) decreased from 1181.46 ng/ml to normal. The liver function of the patient remained Child-Pugh A throughout [22].

A combination of atezolizumab and bevacizumab was approved as a first-line therapeutic choice for advanced or metastatic HCC [23]. Recently, a phase II clinical trial of sintilimab (200 mg IV Q3W) combined with IBI305 (15 mg/kg IV Q3W) as a first-line treatment option for advanced HCC (NCT03794440, ORIENT-32) was performed by Fan et al. They showed that mPFS reached 8.4 months (95% CI, 5.6, not reached) but not OS. DCR was a preeminent 83.3%, while ORR was 25%, with an acceptable safety profile. Since a total of 24 patients were enrolled in the phase II clinical study, a large patient population is recommended to ascertain our findings. However, a phase III clinical trial of this study to compare the efficacy of sintilimab plus IBI305 and sorafenib is ongoing [24].

Gastric Cancer

A phase Ib clinical trial (NCT02937116) of sintilimab combined with oxaliplatin/capecitabine (CapeOx) as the first-line therapeutic option was performed for patients with locally advanced or metastatic gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma without previous systemic treatment. The enrolled patients had more than 4 cycles of treatment with the median treatment duration being 6.2 months (range 2.1–10.4). Grade 3–4 TRAEs occurred in 55.0% out of 20 patients, in which the most frequent TRAE was a decrease in platelet counts (n = 16, 80.0%). There were no treatment associated fatal cases with one case being discontinued from treatment due to AE. The median time to response (mTTR) was 2.1 months (95% CI: 2.0–2.1) while the median duration of response (mDOR) was 5.9 months (95% CI: 4.8–7.2). The PFS of sintilimab-chemotherapy was 7.5 months (95% CI: 6.2–9.4), while mOS was not met by May 1, 2019. ORR was 85% (95% CI: 62.1–96.8%). Notably, DCR achieved 100.0% (95% CI: 83.2–100.0%). The OS rates for 6 months and 12 months were 100.0% and 68.0% respectively, suggesting a significant anti-tumor effect and benign tolerability. Interestingly, TMB was not associated with curative effects in the trial [25]. ATTRACTION-4 was a clinical trial of nivolumab combined with SOX/CapeOX among patients with advanced G/GEJ cancer as the first-line therapy. The ORR of nivolumab plus S-1 and oxaliplatin (SOX) was 57.1% (95% CI: 34.0–78.2), while that of nivolumab plus capecitabine and oxaliplatin (CapeOX) was 76.5% (95% CI: 50.1–93.2) [26]. Similarly, KEYNOTE-059 and KEYNOTE-062 determined the efficacy of pembrolizumab ± chemotherapy as the first-line therapy in advanced G/GEJ cancer [27, 28]. ORRs of the pembrolizumab group were 60.0% for KEYNOTE-059 [27] and 48.6% (CPS ≥ 1) for KEYNOTE-062 [28]. Comparatively, as a first-line option, the ORR of sintilimab with chemotherapy was superior to those of standardized chemotherapy, or pembrolizumab/nivolumab ± chemotherapy in advanced G/GEJ cancer.

Cervical Cancer

For patients previously subjected to multiple chemotherapy sessions, recurrent or metastatic advanced cervical cancer (CC) (PD-L1 expression>1%, ECOG of 0–1), sintilimab (200 mg, intravenously, Q3W) combined with anlotinib (10 mg orally, QD, d1–14; every 21 days) was performed until disease progression, death or intolerable toxicity (ChiCTR1900023015). The study set ORR as the primary endpoint, while OS, PFS, and DCR were determined as the secondary endpoints. The maximum ORR and DCR were 54.5% and 100%, respectively. The mPFS and mOS had not been met by then, while the original regimen was deemed to be tolerable given that the most common AEs were G1/2 [29]. Due to their affordability, both sintilimab and anlotinib from China, are potential drugs for use as a combination regimen for CC.

Other types of tumors

As the second-line option after chemotherapy, CR was achieved after the application of 3 cycles of sintilimab (200 mg Q3W) on an advanced intrahepatic cholangiocarcinoma (ICC) patient with low microsatellite instability (MSI-L) and TMB. Sintilimab was discontinued due to the adrenal insufficiency attack after a total of 34 cycles of ICIs, which was relieved by hydrocortisone (20 mg/d) administration [30]. Furthermore, as a third-line strategy, a trial of sintilimab combined with tegafurgimeracil-oteracil potassium capsules was performed on an ICC case with multiple metastases. PR was achieved after 6 cycles of treatment, and the survival quality of the patient was enhanced significantly [31].

Apart from the common cancer types, sintilimab was involved in suppressing tumor progression on a KRAS positive patient with hepatoid adenocarcinoma (HAC), a sort of rare tumor secreting AFP with morphological similarities to HCC, and eventually achieved a 52-month OS [32].

Analysis of the above clinical trials (Table 2) and specific cases showed the potential of sintilimab as an equivalent to pembrolizumab and nivolumab.

Table 2 Completed Sintilimab-based Clinical Trials

Adverse effects

Not only effectiveness but also safety is of concern when using sintilimab in solid tumors. ICIs activate the immune system in patients with cancer and promote the in vivo killing effect of T cells. Excessive activation of the immune-system leads to immune-related adverse events (irAEs) in the human body [33]. Primary causes of irAEs mechanism are the disturbance of immune balance, which might be explained by several potential hypotheses. For instances, when immune cells are over-active, cytotoxic T cells cross-react between tumor and normal cells. In addition, the increased inflammatory factors as well as the rise in the number of auto-immune antibodies, explain this phenomenon [34,35,36]. The irAEs are characterized by diarrhea, hepatitis, rash, pneumonia, thyroid dysfunction and others [33].

Common sintilimab-associated irAEs are characterized by pyrexia, hypothyroidism, rash, pneumonitis, fatigue and decreased platelet count [6, 12, 25]. Infrequent irAEs symptoms include PNSs [21], immune induced-myositis/myocarditis and rhabdomyolysis [37], high-CPK asymptomatic hypothyroid myopathy [38], cardiac toxicity [18], and adrenal insufficiency [30]. Furthermore, a refractory colon cancer patient exhibited systemic inflammatory response syndrome (SIRS) after sintilimab administration, leading to pulmonary fibrosis [39]. Cytokine release syndrome (CRS) along with multiple-organ injury was incurred after several cycles of sintilimab combined with chemotherapy on a patient with unresectable esophageal cancer (ESC) [40]. However, the above irAEs are controllable, and consistent with known toxicities.

Anti-PD-1/PD-L1 blockades presented a high synergistic effect when incorporated with other treatments [41, 42]. Previous studies revealed the anti-angiogenesis drugs potential to improve the efficacy of immunotherapy by reducing tumor hypoxia, improving perfusion, and reforming the tumor microenvironment [43, 44]. For example, clinical trials on the treatment of advanced HCC using immune checkpoint inhibitors alone exhibited a poor efficacy [45, 46]. However, immunotherapy combined with anti-angiogenesis therapy presented a synergistic effect on the mechanism of action [23, 46], which was proved by a trial of IMbrave 150 in unresectable HCC patients [23]. Strategies that combine other types of immunomodulators, chemotherapy, and molecular targeted treatments either in vivo or in vitro are ongoing [5].

Over the past few decades, clinical trials of new drugs in China were lagging behind other regions and their approval in the Chinese market were delayed for years. With the advance of the National Medicine Products Administration (NMPA) reform, more international pharmaceutical companies will perform clinical trials in China after realizing the globalization of drug development [47]. Interestingly, sintilimab can potentially benefit patients from underdeveloped areas or developing countries with promising anti-tumor effects as well as its affordability.

Several sintilimab-based clinical trials on malignancies are ongoing in multi-center in China, among the key trials are elaborated in ( 3):

Table 3 Main Ongoing Clinical Trials


This article summarizes the progress of sintilimab in the field of cancer treatments, generalizing the efficacy and safety of sintilimab alone or combined regimens in multiple solid tumors. With the promising potential and application prospect of sintilimab, a vast number of multicenter, large-scale prospective clinical trials are going ahead in China to further determine its safety and effectiveness for cancer therapy. Hitherto, sintilimab has only been approved for use in RR-cHL, and it could be expected to be approved for more cancer types and admitted to realize its globalization.

Availability of data and materials

All data analysed during this study are included in this published article.



Programmed cell death protein 1


Programmed cell death protein 1 ligand 1/2


Cytotoxic T lymphocyte antigen-4


Immune checkpoint inhibitors


Objective response rate


Diffuse large B cell lymphoma


Non-small lung cancer


Major pathologic response


Pathologic complete responses


Positron emission tomography-computed tomography


Tumor mutation burden


Disease control rate


Epidermal growth factor receptor


Anaplastic lymphoma kinase


Progression-free survival


Overall survival


Time to response


Duration of response


European Society for Medical Oncology


Partial remission


Tumor proportion score


median time to tumor progression


Complete remission




Hepatocellular carcinoma


Cervical cancer


Intrahepatic cholangiocarcinoma


Hepatoid adenocarcinoma


Gastric/gastroesophageal junction adenocarcinoma


White blood cell


Treatment related adverse event


  1. 1.

    Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.

    Article  Google Scholar 

  2. 2.

    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    CAS  Article  Google Scholar 

  3. 3.

    Carlisle JW, Steuer CE, Owonikoko TK, Saba NF: An update on the immune landscape in lung and head and neck cancers. CA Cancer J Clin. 2020;0:1–13.

  4. 4.

    Hoy S. Sintilimab: First Global Approval. Drugs. 2019;79(3):341–6.

    CAS  Article  Google Scholar 

  5. 5.

    Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, Ni H, Chen B, Xiong Y, Liu Y, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. 2019;11(8):1443–51.

    CAS  Article  Google Scholar 

  6. 6.

    Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–9.

    Article  Google Scholar 

  7. 7.

    Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.

    CAS  Article  Google Scholar 

  8. 8.

    Talotta R, Rucci F, Canti G, Scaglione F. Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases. Immunotherapy. 2019;11(3):241–54.

    CAS  Article  Google Scholar 

  9. 9.

    Ansell S. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma. Lancet Haematol. 2019;6(1):e2–3.

    Article  Google Scholar 

  10. 10.

    Shi Y, Li Q, Zhang W, Nan Y, Yang T, Liang X, Xiao C, Guo B, Xiang Y. Sintilimab as salvage treatment in an HIV patient with relapsed/ refractory Hodgkin: a case report. Ann Palliat Med. 2020;9(4):23.

  11. 11.

    Zheng R, Chen X, Wang C, Qin P, Tan H, Luo X. Triplet therapy with PD-1 blockade, histone Deacetylase inhibitor, and DNA methyltransferase inhibitor achieves radiological response in refractory double-Expressor diffuse large B-cell lymphoma with 17p deletion. Case Rep Hematol. 2020;2020:8879448.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816–26.

    CAS  Article  Google Scholar 

  13. 13.

    Han B, Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Han Y. Efficacy and safety of Sintilimab with Anlotinib as first-line therapy for advanced non-small cell lung Cancer (NSCLC). J Thorac Oncol. 2019;14(10):S129.

    Article  Google Scholar 

  14. 14.

    Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11). J Thorac Oncol. 2020;15(10):1636–46.

  15. 15.

    C. Zhou LW, Y. Fan, Z, et al. : ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC). Ann Oncol 31 (suppl_4): S1142-S1215 2020.

  16. 16.

    Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, et al. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunol Immunother. 2020.

  17. 17.

    Thompson JA. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. J Natl Compr Cancer Netw. 2018;16(5S):594.

  18. 18.

    Shan Q, Wang H, Han X, Guo J, Wang Z. Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. Thorac Cancer. 2020;11(10):3001–6.

  19. 19.

    Zhang L, Mai W, Hao B, Jiang W, Geng Q. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: a case report. Medicine. 2020;99(21):e19790.

    Article  Google Scholar 

  20. 20.

    Zhang Y, Zhao M, Cao S, Zhang X, Du Y. Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: a case report. Thorac Cancer. 2020;11(9):2717–22.

  21. 21.

    Kang K, Zheng K, Zhang Y. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy. J Immunother. 2020;43(5):165–8.

    CAS  Article  Google Scholar 

  22. 22.

    Duan X, Zhang H, Zhou L, Jiang B, Mao X. Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis. Dig Liver Dis. 2020, 52(7):794–796.

  23. 23.

    Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T, Kudo M, Breder V, Merle P, Kaseb A, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–905.

    CAS  Article  Google Scholar 

  24. 24.

    ZR FJ, Xu J, et al. Sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma. Ann Oncol. 2020;31(suppl_4):S629–44.

    Article  Google Scholar 

  25. 25.

    Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, et al. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer. 2020;20(1):760.

    CAS  Article  Google Scholar 

  26. 26.

    Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30(2):250–8.

    CAS  Article  Google Scholar 

  27. 27.

    Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019;22(4):828–37.

    CAS  Article  Google Scholar 

  28. 28.

    Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al. Efficacy and safety of Pembrolizumab or Pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric Cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–80.

  29. 29.

    CC QX, Sun Y, et al. A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC). Ann Oncol. 2020;31(suppl_4):S551–89.

    Article  Google Scholar 

  30. 30.

    Zhang J, Wu L, Liu J, Lin M. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review. Immunotherapy. 2020;12(8):555–61.

    Article  Google Scholar 

  31. 31.

    Liu J, Wang C, Cao L, Li S. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report. Ann Palliative Med. 2020;9(2):497–503.

    Article  Google Scholar 

  32. 32.

    Chen L, Han X, Gao Y, Zhao Q, Wang Y, Jiang Y, Liu S, Wu X, Miao L. KRASAnti-PD-1 therapy achieved disease control after multiline chemotherapy in Unresectable -positive Hepatoid lung adenocarcinoma: a case report and literature review. OncoTargets Ther. 2020;13:4359–64.

    Article  Google Scholar 

  33. 33.

    Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annal Oncol. 2015;26(12):2375–91.

    CAS  Article  Google Scholar 

  34. 34.

    Choi J, Lee S. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9.

    Article  Google Scholar 

  35. 35.

    Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143–53.

    Article  Google Scholar 

  36. 36.

    Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.

    CAS  Article  Google Scholar 

  37. 37.

    Xing Q, Zhang ZW, Lin QH, Shen LH, Wang PM, Zhang S, Fan M, Zhu B. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma. Ann Transl Med. 2020;8(5):250.

    CAS  Article  Google Scholar 

  38. 38.

    Ni J, Zhang L, Zhang X. Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy. Eur J Cancer. 2020;128:57–9.

    CAS  Article  Google Scholar 

  39. 39.

    Hu J, Li Y, Chen X, Luo C, Zuo X. Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab. J Clin Pharm Ther. 2020.

  40. 40.

    Gao C, Xu J, Han C, Wang L, Zhou W, Yu Q. An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report. Ann Palliat Med. 2020;9(4):2393–9.

    Article  Google Scholar 

  41. 41.

    Johnson CB, Win SY. Combination therapy with PD-1/PD-L1 blockade: an overview of ongoing clinical trials. Oncoimmunology. 2018;7(4):e1408744.

    Article  Google Scholar 

  42. 42.

    Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286–301.

    CAS  Article  Google Scholar 

  43. 43.

    Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–22.

    CAS  Article  Google Scholar 

  44. 44.

    Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–40.

    CAS  Article  Google Scholar 

  45. 45.

    Finn R, Ryoo B, Merle P, Kudo M, Bouattour M, Lim H, Breder V, Edeline J, Chao Y, Ogasawara S, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202.

    CAS  Article  Google Scholar 

  46. 46.

    Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020; 21(6):808–20.

  47. 47.

    Ye X, Wang QL, Wang HX. New era of drug innovation in China. Acta Pharm Sin B. 2019;9(5):1084–5.

    Article  Google Scholar 

Download references


Not applicable.


Not applicable.

Author information




The authors acknowledged Yong Yi for conducting the conception and design of the study and revised the final version for publishing. We thank Xuhong Liu for collecting, analyzing all the data and drafting the article. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Yong Yi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Yi, Y. Recent updates on Sintilimab in solid tumor immunotherapy. Biomark Res 8, 69 (2020).

Download citation


  • Solid tumors
  • Sintilimab
  • PD-1 inhibitor
  • Immunotherapy
  • Clinical Progress